Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH)

The American company, Cumberland Pharmaceuticals, is conducting a phase 2 clinical study evaluating the safety and effectiveness of a new oral drug product in patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH) associated with their scleroderma. The study is open at 6 Scleroderma Centers of Excellence and opening at more centers with active Scleroderma Research programs.

General study information can be found at the study’s NCT website (NCT02682511). Eligible subjects will be reimbursed for their time and travel. If you are interested in learning more, please contact us at 615-627-4121 or bkaelin@cumberlandpharma.com

At the moment the study is targeted Australia, Canada, South Africa, India and U.S.

Details on the trial – please go to: https://clinicaltrials.gov/ct2/show/NCT02682511?cond=systemic+sclerosis+ifetroban&rank=1  

 

Tagged: ,

Comments are closed.